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Background
An early diagnosis of disseminated intravascular coagulation (DIC) before its progression 
to an overt stage is necessary for early treatment and positive outcomes. In 2001, the 
Scientific and Standardization Committee (SCC) of the International Society on 
Thrombosis and Hemostasis (ISTH) proposed new criteria for the preclinical diagnosis 
of overt and non-overt DICs. We investigated the clinical usefulness of the modified ISTH 
criteria for non-overt DIC diagnosis. 
Methods
We enrolled 296 DIC patients (170 males and 126 females) admitted and evaluated at 
the Gangnam Severance Hospital, Seoul, Korea, between March 2006 and April 2007. 
Hemostatic tests, including platelet counts, prothrombin time (PT), D-dimer levels with 
antithrombin, and protein-C levels, were evaluated by excluding negative scores with clin-
ical signs, in which more than 5 points of interest denoted non-overt DIC. Mortality rates 
were also evaluated. 
Results
There were 289 patients with increased D-dimer levels and significant parametric changes 
suggesting DIC progression. Protein C and antithrombin levels were lower (99.2% each) 
and appeared earlier in patients with non-overt DIC than in patients with overt DIC. In 
all, 125 (43.3%) patients had non-overt DIC and, of which 27 died (mortality rate, 21.6%). 
The sensitivity and specificity for mortality were 73.0% and 55.9%, respectively, which 
were same as those for the original ISTH criteria.
Conclusion
The modified ISTH criteria can be used for the early detection of non-overt DIC, and may 
be useful for the improvement of outcomes of non-overt DIC patients.
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INTRODUCTION
  In 2001, the Scientific and Standardization Subcommittee 
(SSC) on disseminated intravascular coagulation (DIC) of 
the International Society of Thrombosis and Hemostasis 
(ISTH) proposed the current working definitions of overt 
and non-overt DIC [1]. Non-overt (early) DIC is a subtle 
hemostatic dysfunction that has not yet reached the decom-
pensation stage, as in overt DIC. The ISTH SSC proposed 
a scoring system for the diagnosis of non-overt DIC on the 
basis of the clinical conditions and abnormal results of global 
hemostatic tests such as the platelet count, prothrombin time 
(PT), D-dimer, antithrombin (AT), and protein C (PC) levels; 
this system is similar to the defined scoring system for overt 
DIC. However, its clinical application is limited for scoring 
negative values. We investigated the usefulness of the ISTH 
criteria with minor modifications in diagnosing non-overt 
DIC (Table 1).Korean J Hematol 2010;45:260-3.
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Table 1. Diagnostic criteria for overt DIC and non-overt DIC by ISTH.
Overt DIC
Non-overt DIC
By original ISTH criteria By modified ISTH criteria
Platelet count (/μL)  50,000-100,000 : 1 point
＜50,000 : 2 point
Underlying disorder 
associated with DIC:
2 points +
Increase: -1 point
Decrease: 1 point
Only decrease: 1 point
 (＜100,000)
PT (s) Prolongation of PT
3-6 : 1 point
≥6 : 2 point
+
Not prolonged: -1 point
Prolonged: 1 point
Only prolonged: 1 point
(＞3 s)
Fibrinogen (mg/dL) 100 : 1 point
D-dimer (μg/mL) 0.5-1 : 1 point
1-3 : 2 point
≥3 : 3 point
Not increase: -1 point
Increased: 1 point
Always increase: 1 point
(≥0.5)
Protein C activity (%) Normal: -1 point
Decreased: 1 point
Decrease: 1 point 
(＜70)
Antithrombin III (%) Normal: -1 point
Decreased: 1 point
 Decrease: 1 point 
(＜80)
Total  ≥5 points ≥5 points  (2 +                                                               )
Table 2. Non-DIC and non-overt DIC template scores by original/modified ISTH criteria.
Score
Non DIC
Subtotal
Non-overt DIC
Subtotal
Overt DIC
Subtotal Total
0 1   2 3 4 567 56 7
No. of patients 7/0 7/0 6/0 68/70 68/64 150/134 74/82 41/42 1/1 116/125 13 13 4 30 296/289
MATERIALS AND METHODS
  We enrolled 296 patients who were consecutively admit-
ted for the treatment of various conditions associated with 
DIC at the Gangnam Severance Hospital, Seoul, Korea, be-
tween March 2006 and April 2007. There were 170 males 
and 126 females, with a median age of 64 years. Known 
clinical signs associated with DIC were used to confirm 
diagnoses. 
1. Laboratory evaluation 
  Hemostatic tests, including platelet counts (Beckman 
Coulter Counter, Brea, CA, USA) and prothrombin time 
(STA NEOPLASTINE CI PLUS; Diagnostica, France), were 
evaluated at admission, daily during hospital stay, and at 
all follow-up visits. Serum fibrinogen (STA FIBRINOGEN; 
Diagnosica, France) and D-dimer (STA LIATEST D-dimer; 
Immunoturbidimetric assay, Diagnostia, France) levels with 
antithrombin (STA-STACHROM AT; Colorimetric assay, 
Diagnostica, France) and protein C (STA-STACHROM PROTEIN 
C; Colorimetric assay, Diagnostica, France) activities were 
evaluated at admission, during hospital stay biweekly or 
weekly, and at all follow-up visits.
  D-dimer levels higher than 0.5 μg/mL were considered 
as elevated. Antithrombin and protein C activities less than 
80% (normal, 88-134%) and 70% (normal, 70-130%) of nor-
mal, respectively, were considered as reduced. 
2. Definition of non-overt DIC
  We modified the ISTH criteria for non-overt DIC diag-
nosis; for all paramedic applications and rejected any negative 
scores that did not accurately reflect laboratory data. Like 
in the ISTH criteria, a score of 5 or greater was denoted 
as non-overt DIC. When the modified criteria for non-overt 
DIC was used, the number of non-overt DIC diagnoses in-
creased from 116 to 125 and the number of non-DIC diag-
noses decreased from 150 to 134 (Table 2). Mortality rate 
was also calculated during the study period, and the sensi-
tivity and specificity were determined. 
3. Statistical analysis 
  Differences between groups were analyzed using the 
Student's t test, and a P-value of less than 0.05 was considered 
as significant. Mortality rates with sensitivity and specificity 
were calculated by the exact binomial method with a 95% 
confidence interval.
RESULTS
1. Clinical characteristics
  Underlying causative diseases included infections, trauma, 
and malignancy (in order of prevalence) (Table 3). 
2. Parametric changes according to DIC status
  Of the 296 enrolled patients, 7 had stable D-dimer levels Korean J Hematol 2010;45:260-3.
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Table 3. Underlying causative diseases according to DIC status. 
Underlying diseases Non DIC Non-overt DIC Overt DIC
Infection
Trauma
Malignancy
Vascular abnormalities
Liver disease
Obstetric disease
Others
37
38
17
9
0
2
31
33
32
17
18
3
2
20
13
7
7
0
1
0
2
Total 134 125 30
Table 4. Hemostatic parameters in living/deceased patients and associated number of parametric changes.
Parameter
Non-DIC (N=134) Non-overt DIC (N=125) Overt DIC (N=30)
Living/deceased   N Living/deceased   N Living/deceased   N
Platelet count (/μL)  295,300/233,000 (2) 235,900/194,000 (28) 74,000/37,300 (27)
PT (s)  14.3/15.3 (4) 16.4/18.7 (18) 21.4/36.2 (30)
Fibrinogen (mg/dL) 502.5/492.8 (0) 458.6/486.9 (1) 298.1/135.8 (3)
D-dimer (μg/mL) 3.3/6.2 (134) 5.9/4.6 (125) 15.3/42.8 (30)
Protein C activity (%) 99.5/104.3 (21) 51.4/43.0 (124) 32.7/28.2 (30)
Antithrombin (%)  97.5/101.3 (35) 64.5/54.0 (124) 60.8/43.4 (30)
Table 5. Non-DIC and non-overt DIC template scores in relation to the outcomes of the original/modified ISTH criteria.
Score
Non-DIC
Subtotal
Non-overt DIC
Subtotal Total
01234  567
No. of patients 7/0 7/0 6/0 68/70 68/64 150/134 74/82 41/42  1/1 116/125 266/259
Death 0/0 0/0 1/0 6/7 3/3 10/10 15/15 12/12 0/0 27/27 37/37
Overt DIC progression 1/0 1/0 3/3 1/1 4/4 5/4
and no parametric changes, including protein C and antith-
rombin.
  In all, 289 patients with increased D-dimer levels and 
significant parametric changes showed progression to either 
overt or non-overt DIC. However, no differences in the 
parameters were found between the patients who survived 
and those who died during the course of the study. 
  Of the 125 patients with non-overt DICs, 28 (22.4%) and 
18 (14.4%) showed slightly increased platelet levels and PT 
levels, respectively. These relatively small changes in non- 
overt DIC patients were abruptly increased in patients with 
overt DIC. Moreover, 124 (99.2%) patients with non-overt 
DIC showed decreased protein C and antithrombin levels 
that were almost similar to those noted in overt DIC patients. 
However, the levels decreased earlier in non-overt DIC pa-
tients than in overt DIC patients (Table 4). 
3. Outcomes according to DIC status
  Of the 289 patients with increased D-dimer levels, 134 
(46.4%) were diagnosed with non-DIC, of which 10 died 
(mortality rate, 7.5%). 
  In all, 125 (43.3%) patients were diagnosed with non-overt 
DIC, of which 27 died (mortality rate, 21.6%), including 
4 patients who progressed to overt DIC. The sensitivities 
for mortality were 73.0% for non-overt DIC, which was 
same as that of the original ISTH criteria and the specificities 
were 61.1% and 55.9%, respectively. In all, 30 (10.3%) pa-
tients were diagnosed with overt DIC, of which 12 died 
(mortality rate, 40.0%). This mortality rate was higher than 
that of non-overt DIC patients (P＜0.05) (Tables 5, 6).
DISCUSSION
  DIC is characterized by systemic blood coagulation hyper-
activation resulting in the consumption of platelets and coag-
ulation factors, potentially leading to severe bleeding. Fibri-
nolytic activity depression and fibrin deposition occurs in 
the microcirculation, contributing to multiple organ failure. 
DIC is typically associated with several predisposing causes. 
In this study, the major underlying disorders associated with 
non-overt DIC included infection, trauma, and malignancy, 
which are similar to those that have been previously reported [2].
  In 2001, the SSC of the ISTH recommended a new scoring 
system for non-overt DIC diagnosis [1]. Toh and Downey 
[2] showed that this proposed scoring system could be effec-
tively applied. However, diagnosing the presence and se-
verity of non-overt DIC using the ISTH scoring system can 
be complicated. For example, utilization of negative scores 
does not accurately reflect parametric changes, and does 
not display significant differences in sensitivity and specific-
ity calculations for mortality. Therefore, in our ISTH modi-
fied criteria, negative scores were rejected: platelet counts 
were increased in 9 cases and this, in combination with Korean J Hematol 2010;45:260-3.
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Table 6. Outcome of each DIC status according to the original/modified ISTH criteria.
No. of cases (%)
by original ISTH criteriaby modified ISTH criteria
Mortality (%) Sensitivity (%)  Specificity (%) P
Non-DIC 150 (50.7) 134 (46.4) 10 (7.5) ＜0.05
＜0.05 Non-overt DIC 116 (39.1) 125 (43.3) 27 (21.6) 73.0/73.0
⎟
⎠
⎞
⎜
⎝
⎛
⎟
⎠
⎞
⎜
⎝
⎛
37
27
37
27
61.1/55.9
⎟
⎠
⎞
⎜
⎝
⎛
⎟
⎠
⎞
⎜
⎝
⎛
222
124
229
140
Overt DIC 30 (10.2) 30 (10.3) 12 (40.0)
P＜0.05, There is higher mortality rate in non – overt DIC patients than the non-DIC group, but lower than overt DIC patients.
elimination of negative scores, increased the number of 
non-overt DIC patients from 116 to 125 and decreased the 
number of non-DIC patients from 150 to 134. There were 
no PT values below the normal limits, and D-dimer with 
protein C and/or antithrombin levels were stable in 7 cases. 
In the remaining 289 cases, changes in plasma protein C 
or antithrombin levels were always observed with an asso-
ciated increase in D-dimer level. A Japanese study reported 
that plasma D-dimer levels increased and plasma protein 
C and antithrombin levels decreased in the non-overt DIC 
cases [3]; our data was consistent with these findings. 
  Although the ISTH scoring system for non-overt DIC al-
lows for the measurement of protein C and antithrombin 
levels, Kinasewitz et al. [4] insisted that the combination 
of scoring abnormal results in the PT, platelet count, and 
D-dimer levels might provide sufficient criteria to diagnose 
DIC without the use of molecular markers. Additionally, 
Toh and Hoots [5] were hesitant to validate the value by 
including PC and AT estimations. However, our data showed 
a good relationship between the 2 parametric changes for 
DIC status. 
  In our study, the mortality rate of non-overt DIC patients 
was 21.6%, including the 4 cases that progressed to overt 
DIC. This rate was lower than those reported in other studies 
[2], where the mortality rate was as high as 78%, which 
was same as that in their overt DIC patients. They showed 
that non-overt DIC itself carries a prognosis independent 
of overt DIC, and suggested that a score of 5 or higher 
may represent a decompensated phase of hemostatic dysfunc-
tion, albeit at an earlier stage than overt DIC. Additionally, 
another study reported mean intervals between non-overt 
and consequent overt DIC and death to be 1 and 5 days, 
respectively [6]. Therefore, a diagnosis of non-overt DIC 
may present a therapeutic window of opportunity for target-
ing treatment. Dhainaut et al. [7] reported a retrospective 
analysis on the use of activated protein C in severe sepsis. 
Patients without overt DIC had a mortality rate of 22.1%, 
but placebo-treated DIC patients had a mortality rate of 
27.1%, with less benefit. In a study involving the KyberSept 
cohort of patients treated with antithrombin, the authors 
did not use negative scores for the decrease in antithrombin 
and protein C activities. A reduction in non-overt DIC patient 
mortality was observed at 28 and 90 days with 25.7 and 
34.6%, compared to mortality rates of 40.9 and 51.8%, re-
spectively, in the placebo groups [8]. These results show 
that an effective method of reducing DIC mortality rates 
is to begin treatment early, while the patients are still in 
the non-overt DIC stage. 
  In conclusion, we attempted to modify the ISTH criteria 
for non-overt DIC diagnosis to allow simple and practical 
early detection of non-overt DIC, which may improve disease 
outcomes.
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